STING is significantly increased in high-grade glioma with high risk of recurrence

References

• Bauchet L, Ostrom QT. Epidemiology and molecular epidemiology. Neurosurg Clin N Am. 2019 Jan;30(1):1–13. doi:10.1016/j.nec.2018.08.010.
   PubMed Web of Science ®Google Scholar
• Berger TR, Wen PY, Lang-Orsini M, Chukwueke UN. World health organization 2021 classification of central nervous system tumors and implications for therapy for adult-type gliomas: a review. JAMA Oncol. Oct 1 2022;8(10):1493–1501. doi:10.1001/jamaoncol.2022.2844.
   PubMed Web of Science ®Google Scholar
• Gallego O. Nonsurgical treatment of recurrent glioblastoma. Curr Oncol. 2015 Aug;22(4):273–281. doi:10.3747/co.22.2436.
   PubMed Web of Science ®Google Scholar
• Kannan S, Murugan AK, Balasubramanian S, Munirajan AK, Alzahrani AS. Gliomas: genetic alterations, mechanisms of metastasis, recurrence, drug resistance, and recent trends in molecular therapeutic options. Biochem Pharmacol. 2022 Jul;201:115090. doi:10.1016/j.bcp.2022.115090.
   PubMed Web of Science ®Google Scholar
• Haase S, Banerjee K, Mujeeb AA, Hartlage CS, Núñez FM, Núñez FJ, Alghamri MS, Kadiyala P, Carney S, Barissi MN. et al. H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models. J Clin Invest. Nov 15 2022;132(22). doi:10.1172/JCI154229.
   PubMed Web of Science ®Google Scholar
• Pang Y, Chen X, Ji T, Cheng M, Wang R, Zhang C, Liu M, Zhang J, Zhong C. The chromatin remodeler ATRX: role and mechanism in biology and cancer. Cancers Basel. Apr 10 2023;15(8):2228. doi:10.3390/cancers15082228.
   PubMed Web of Science ®Google Scholar
• Reislander T, Groelly FJ, Tarsounas M. DNA damage and cancer immunotherapy: a STING in the tale. Mol Cell. Oct 1 2020;80(1):21–28. doi:10.1016/j.molcel.2020.07.026.
   PubMed Web of Science ®Google Scholar
• Fedchenko N, Reifenrath J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue – a review. Diagn Pathol. Nov 29 2014;9(1):221. doi:10.1186/s13000-014-0221-9.
   PubMedGoogle Scholar
• Kulangara K, Hanks DA, Waldroup S, Peltz L, Shah S, Roach C, Juco JW, Emancipator K, Stanforth D. Development of the combined positive score (CPS) for the evaluation of PD-L1 in solid tumors with the immunohistochemistry assay PD-L1 IHC 22C3 pharmDx. J Clin Oncol. 2017;35(15_suppl):e14589–e14589. doi:10.1200/JCO.2017.35.15_suppl.e14589.
   Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioportal. Sci Signal. Apr 2 2013;6(269):l1. doi:10.1126/scisignal.2004088.
   Web of Science ®Google Scholar
• Zhao Z, Zhang KN, Wang Q, Li G, Zeng F, Zhang Y, Wu F, Chai R, Wang Z, Zhang C. et al. Chinese glioma genome atlas (CGGA): a comprehensive resource with functional genomic data from Chinese glioma patients. Genomics, proteomics & bioinformatics. 2021 Feb;19(1):1–12. doi:10.1016/j.gpb.2020.10.005.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Meng F, Wang W, Wang Z, Zhang C, Jiang T. Comprehensive RNA-seq transcriptomic profiling in the malignant progression of gliomas. Sci Data. Mar 14 2017;4(1):170024. doi:10.1038/sdata.2017.24.
   PubMedGoogle Scholar
• Tentori L, Leonetti C, Scarsella M, d’Amati G, Portarena I, Zupi G, Bonmassar E, Graziani G. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood Mar. 2002 15; 99(6): 2241–2244. doi:10.1182/blood.V99.6.2241.
   PubMed Web of Science ®Google Scholar
• Huang F, Mazin AV, Korolev S. A small molecule inhibitor of human RAD51 potentiates breast cancer cell killing by therapeutic agents in mouse xenografts. PloS One. 2014;9(6):e100993. doi:10.1371/journal.pone.0100993.
   PubMed Web of Science ®Google Scholar
• Nishikawa T, Watanabe R, Kitano Y, Yamamichi A, Motomura K, Ohka F, Aoki K, Hirano M, Kato A, Yamaguchi J. et al. Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of grade 2/3 gliomas. Brain Tumor Pathol. 2022 Jan;39(1):14–24. doi:10.1007/s10014-021-00418-x.
   PubMed Web of Science ®Google Scholar
• Liu XY, Gerges N, Korshunov A, Sabha N, Khuong-Quang D-A, Fontebasso AM, Fleming A, Hadjadj D, Schwartzentruber J, Majewski J. et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol. 2012 Nov;124(5):615–625. doi:10.1007/s00401-012-1031-3.
   PubMed Web of Science ®Google Scholar
• Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F, Cree IA. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020 Jan;76(2):182–188. doi:10.1111/his.13975.
   PubMed Web of Science ®Google Scholar
• Floyd W, Pierpoint M, Su C, Patel R, Luo L, Deland K, Wisdom AJ, Zhu D, Ma Y, DeWitt SB. et al. Atrx deletion impairs CGAS/STING signaling and increases sarcoma response to radiation and oncolytic herpesvirus. J Clin Invest. May 18 2023;133(13):1–17. doi:10.1172/JCI149310.
   PubMed Web of Science ®Google Scholar
• Yang Q, Nair S, Laknaur A, Ismail N, Diamond MP, Al-Hendy A. The polycomb group protein EZH2 impairs DNA damage repair gene expression in human uterine fibroids. Biol Reprod. 2016;94(3):69. doi:10.1095/biolreprod.115.134924.
   PubMed Web of Science ®Google Scholar
• Ramanjulu JM, Pesiridis GS, Yang J, Concha N, Singhaus R, Zhang S-Y, Tran J-L, Moore P, Lehmann S, Eberl HC. et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature. 2018 Dec;564(7736):439–443. doi:10.1038/s41586-018-0705-y.
   PubMed Web of Science ®Google Scholar
• Hong Z, Mei J, Li C, Bai G, Maimaiti M, Hu H, Yu W, Sun L, Zhang L, Cheng D. et al. STING inhibitors target the cyclic dinucleotide binding pocket. Proc Natl Acad Sci U S A. Jun 15 2021;118(24):1–10. doi:10.1073/pnas.2105465118.
   Web of Science ®Google Scholar
• Wei X, Zhang L, Yang Y, Hou Y, Xu Y, Wang Z, Su H, Han F, Han J, Liu P. et al. LL-37 transports immunoreactive cGAMP to activate STING signaling and enhance interferon-mediated host antiviral immunity. Cell Rep. May 31 2022;39(9):110880. doi:10.1016/j.celrep.2022.110880.
   PubMed Web of Science ®Google Scholar
• Cheradame L, Guerrera IC, Gaston J, Schmitt A, Jung V, Goudin N, Pouillard M, Radosevic-Robin N, Modesti M, Judde J-G. et al. STING protects breast cancer cells from intrinsic and genotoxic-induced DNA instability via a non-canonical, cell-autonomous pathway. Oncogene. 2021 Dec;40(49):6627–6640. doi:10.1038/s41388-021-02037-4.
   PubMed Web of Science ®Google Scholar
• Berger G, Knelson EH, Jimenez-Macias JL, Nowicki MO, Han S, Panagioti E, Lizotte PH, Adu-Berchie K, Stafford A, Dimitrakakis N. et al. STING activation promotes robust immune response and NK cell–mediated tumor regression in glioblastoma models. Proc Natl Acad Sci U S A. Jul 12 2022;119(28):e2111003119. doi:10.1073/pnas.2111003119.
   PubMed Web of Science ®Google Scholar
• Gao Y, Zheng X, Chang B, Lin Y, Huang X, Wang W, Ding S, Zhan W, Wang S, Xiao B. et al. Intercellular transfer of activated STING triggered by RAB22A-mediated non-canonical autophagy promotes antitumor immunity. Cell Res. 2022 Dec;32(12):1086–1104. doi:10.1038/s41422-022-00731-w.
   PubMed Web of Science ®Google Scholar